NCT05509816View on ClinicalTrials.gov

A Study of Imlunestrant (LY3484356) in Healthy Women

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Healthy

Interventions

DRUG

Midazolam

Administered orally.

DRUG

Imlunestrant

Administered orally.

Trial Locations (2)

32117

LabCorp CRU, Inc., Daytona Beach

75247

LabCorp CRU, Inc., Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY